Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
- Redburn Atlantic analyst Timm Schulze-Melander initiated coverage on NVIDIA Corporation (NASDAQ:NVDA) with a Buy rating and announced a price target of $178. Nvidia shares closed at $145.26 on Monday. See how other analysts view this stock.
- Benchmark analyst Matthew Harrigan initiated coverage on VEON Ltd. (NASDAQ:VEON) with a Buy rating and announced a price target of $48. VEON shares closed at $33.17 on Monday. See how other analysts view this stock.
- UBS analyst Eliana Merle initiated coverage on Altimmune, Inc. (NASDAQ:ALT) with a Buy rating and announced a price target of $26. Altimmune shares closed at $7.35 on Monday. See how other analysts view this stock.
- Capital One analyst Dan Guglielmo initiated coverage on FrontView REIT, Inc. (NYSE:FVR) with an Overweight rating and announced a price target of $22. FrontView REIT shares closed at $18.97 on Monday. See how other analysts view this stock.
- UBS analyst Eliana Merle initiated coverage on Sagimet Biosciences Inc. (NASDAQ:SGMT) with a Buy rating and announced a price target of $12. Sagimet Biosciences shares closed at $5.85 on Monday. See how other analysts view this stock.
Considering buying NVDA stock? Here's what analysts think:
Read More:
- Jim Cramer: This Tech Stock Can 'Go To 160,' Recommends Buying Domino's Pizza
